FDA Lifts Clinical Hold on Vanda Pharmaceuticals' Tradipitant for Motion Sickness Development

FDA Lifts Clinical Hold on Vanda Pharmaceuticals' Tradipitant Development

Vanda Pharmaceuticals Inc. achieves a significant milestone as the U.S. Food and Drug Administration (FDA) lifts the partial clinical hold on its investigational drug tradipitant. This decision follows Vanda's formal dispute resolution request and a swift re-evaluation by the FDA's Center for Drug Evaluation and Research (CDER) leadership. The FDA's newfound position recognizes motion sickness as an acute condition, allowing tradipitant to be administered without the previous restriction of limiting doses to 90. This outcome not only enables Vanda to broaden its clinical studies on tradipitant for motion sickness but also eliminates the necessity for an additional six-month toxicity study in dogs that was previously required.

Tradipitant is positioned to become a groundbreaking treatment in the realm of motion sickness, potentially marking the first new pharmacologic solution for this condition in over four decades. With the FDA’s decision, Vanda can now pursue extensive clinical trials to substantiate the efficacy and safety of tradipitant in this area. Moreover, the review of Vanda's comprehensive New Drug Application (NDA) for tradipitant, aimed at preventing vomiting associated with motion, remains on track, anticipating a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025. This timeline sets the stage for a potential market entry that could reshape the treatment landscape for motion sickness.

Vanda Pharmaceuticals’ President and CEO, Mihael H. Polymeropoulos, M.D., expresses gratitude toward the FDA for their thorough and expedited review process. He emphasizes the strength of the collaborative framework that facilitated this favorable outcome. Vanda's commitment to addressing unmet medical needs through innovative therapies extends beyond motion sickness, as tradipitant is also in clinical development for other indications, such as gastroparesis and nausea induced by GLP-1 receptor agonists. This multifaceted approach underscores Vanda's dedication to pioneering treatments that enhance patient care and quality of life.

In addition to the positive developments surrounding tradipitant, Vanda Pharmaceuticals continues to focus on its broader pipeline of therapies aimed at various indications. The company’s strategic vision remains dedicated to revolutionizing treatment options for patients who face significant medical challenges. The lifting of the clinical hold on tradipitant marks a pivotal point in Vanda's journey, promising to bring much-needed advancements to the field of pharmacologic treatments for motion sickness and beyond. For more updates, Vanda invites interested parties to visit their website and follow their activities on social media.